O USO DA CANNABIS MEDICINAL NOS PACIENTES COM DOR CRÔNICA

Luisa Teixeira Silveira; Maria Letícia  Carvalho da Cruz Ramos; Alejandra Debbo; Maria Elisa Sobral  Vila Nova de Carvalho Vieira; Gabriela Peres de Oliveira Krauss; Marina Mendes Teixeira; Maria Steal Carvalho da Cruz Ramos; Maria Isabelly Alves Pereira Barbosa

doi:10.36489/saudecoletiva.2023v13i88p13455-13475

Authors

Luisa Teixeira Silveira UNIVERSIDADE TIRADENTES https://orcid.org/0000-0003-1325-3296
Maria Letícia Carvalho da Cruz Ramos Universidade Tiradentes https://orcid.org/0000-0001-5909-568X
Alejandra Debbo Universidade Federal de Sergipe https://orcid.org/0000-0002-7743-5921
Maria Elisa Sobral Vila Nova de Carvalho Vieira Universidade Tiradentes https://orcid.org/0000-0003-1636-7408
Gabriela Peres de Oliveira Krauss Universidade Tiradentes https://orcid.org/0000-0002-2863-9549
Marina Mendes Teixeira Universidade Tiradentes https://orcid.org/0009-0003-0677-7849
Maria Steal Carvalho da Cruz Ramos Universidade de Salvador https://orcid.org/0000-0003-3269-9357
Maria Isabelly Alves Pereira Barbosa Universidade de Salvador https://orcid.org/0009-0004-6467-4730

DOI:

https://doi.org/10.36489/saudecoletiva.2023v13i88p13455-13475

Keywords:

Cannabis medicinal; Chronic pain; Treatment

Abstract

Chronic pain (CD) has a significant impact on the population's quality of life (QoL). It has an impact on functional capacity and can influence higher levels of dependence, sleep disorders, changes in mood and appetite. The discovery of the endocannabinoid system in pain has been shown to improve the QoL of individuals with CD. This study seeks to analyze the use of medicinal cannabis (CM) through the therapeutic experience of patients diagnosed with chronic pain, observing the interference with pain, sleep, mood and QoL and the occurrence of side effects (CE). Its a longitudinal observational, descriptive and prospective. The collection was carried out using a digital form answered at the beginning of use of the cannabinoid, after the first month and in the third month of use. The data revealed an association between the use of CM with improved QoL and a significant deterioration in pain, mood and sleep. There were no significant CEs.

References

AGUIAR DP, et al. Prevalence of chronic pain in Brazil: systematic review. BrJP. 2021;(4):257-267.

DS KANEMATSU JAQUELINE, et al. Impacto da dor na qualidade de vida do paciente com dor crônica. Revista de Medicina. 2022;3:101.

COSTA ANE, NAPOLI AER. Revisão bibliográfica da abordagem do tratamento da dor crônica não oncológica, com base na escada analgésica da organização mundial de saúde. Brazilian Journal of Health Review. 2022 Aug 16;5(4):14365–81.

MATIAS, GF, et al. Uso de Cannabis para tratamento da dor crônica: uma revisão sistemática. Research, Society and Development. 2022;11(3).

NASCIMENTO DCH, SAKATA RK. Dependência de opioide em pacientes com dor crônica. Revista Dor. 2011 Jun;12(2):160–5.

CANNABIS MEDICINAL: Conselho Federal de Medicina vai na contramão do mundo [Internet]. Brazil Journal. 2022 [cited 2023 Oct 21]. Available from: https://braziljournal.com/cannabis-medicinal-conselho-federal-de-medicina-vai-na-contramao-do-mundo/

FINN DAVID P, et al. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162:S5-S25.

CAMPOLINA AG, et al. Validação da versão brasileira do questionário genérico de qualidade de vida short-form 6 dimensions (SF-6D Brasil). Ciência & Saúde Coletiva. 2011 Jul;16(7):3103–10.

ESCALA VISUAL ANALÓGICA -EVA [Internet]. Available from: https://www.joinville.sc.gov.br/wp-content/uploads/2017/05/Exame-Escala-Visual-Anal%C3%B3gica-EVA.pdf

MAXWELL AE. Comparing the classification of subjects by two independent judges. British Journal of Psychiatry.1970;116:651–655.

STUART AA. Test for Homogeneity of the Marginal Distributions in a Two-Way Classification. Biometrika. 1955;42(3/4):412–416.

FRIEDMAN M. The Use of Ranks to Avoid the Assumption of Normality Implicit in the Analysis of Variance. Journal of the American Statistical Association. 1937;32(200):675.

CONOVER W, IMAN R. Multiple-comparisons procedures. Informal report. Los Alamos, NM (United States): [s.n.].

MANN HB, WHITNEY DR. On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other. The Annals of Mathematical Statistics. 1947;18(1):50–60.

SHAPIRO SS, WILK MB. An Analysis of Variance Test for Normality (Complete Samples). Biometrika. 1965;52(3/4):591–611.

THE R CORE TEAM R. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. 2023.

PORTER B, et al. Cannabidiol (CBD) use by older adults for acute and chronic pain. Journal of gerontological nursing. 2021;47(7):6-15.

SURAEV A, et al. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ open. 2020;10(5):034421.

BLANTON HENRY L, et al. Sex differences and the endocannabinoid system in pain. Pharmacology Biochemistry and Behavior. 2021;202:173107.

RENSLO B, et al. Medical Cannabis Use Reduces Opioid Prescriptions in Patients With Osteoarthritis. Cureus. 2022;14(1).

MORENO-SANZ G, et al. Sex-Dependent Prescription Patterns and Clinical Outcomes Associated With the Use of Two Oral Cannabis Formulations in the Multimodal Management of Chronic Pain Patients in Colombia. Frontiers in Pain Research. 2022;(3).

URITS I, et al. Adverse effects of recreational and medical cannabis. Psychopharmacology bulletin. 2021;51(1):94.

BOEHNKE KEVIN F, et al. Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Current Rheumatology Reports. 2022;24(7): 238-246.

PETZKE F, et al. Cannabis-based medicines and medical cannabis for chronic neuropathic pain. CNS drugs. 2021;(1):14.

SOLMI M, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. Bmj. 2023;382.

MILLS SEE, et al. Chronic pain: a review of its epidemiology and associated factors in population-based studies. British journal of anaesthesia. 2019;123(2):273-283.

SAUCH VALMANA G, Miró Catalina Q, Vidal-Alaball J. Prevalence and Incidence of Patients With Fibromyalgia in Catalonia Between 2010 and 2017: A Descriptive Observational Study. Journal of Primary Care & Community Health [Internet]. 2022 Jan 1 [cited 2022 Jun 29];13:21501319221094169. Available from: https://pubmed.ncbi.nlm.nih.gov/35465748/

HENDERSON LA, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2. Arthritis & Rheumatology. 2021 Feb 15;73(4).

VILLANUEVA MRB, et al. Efficacy, safety, and regulation of cannabidiol on chronic pain: a systematic review. Cureus. 2022;14(7).

HENSON JD, Vitetta L, Hall S. Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. Inflammopharmacology. 2022 aug [cited 2022 jul 7];30(4):1167-1178. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35796920.

KAUL M, et al. Effects of cannabinoids on sleep and their therapeutic potential for sleep disorders. Neurotherapeutics. 2021;18(1):217-227.